No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANNX Annexon
- 4.565
- -0.485-9.60%
Close Jul 2 16:00 ET
- 4.560
- -0.005-0.11%
Post 18:50 ET
481.21MMarket Cap-3126P/E (TTM)
5.090High4.520Low1.40MVolume4.980Open5.050Pre Close6.57MTurnover1.83%Turnover RatioLossP/E (Static)105.41MShares8.40052wk High1.83P/B349.12MFloat Cap1.57052wk Low--Dividend TTM76.48MShs Float38.010Historical High--Div YieldTTM11.29%Amplitude1.570Historical Low4.708Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Annexon(ANNX.US) Director Buys US$16,000 in Common Stock
$Annexon(ANNX.US)$ Director Carson William H. purchased 3,200 shares of common stock on Jul 1, 2024 at an average price of $5 for a total value of $16,000.Source: Announcement What is statement of cha
Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now?
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating
TD Cowen analyst Phil Nadeau maintains $Annexon(ANNX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.1% and a total average return of 4.9% over the past year.No
Express News | Annexon Shares Are Trading Higher After the Company Announced That It Presented Results From the Phase 3 Trial of C1q-targeted Immunotherapy, ANX005, in Guillain-Barré Syndrome at the 2024 Peripheral Nerve Society Annual Meeting
Annexon Spikes After Updating Late-stage Results for Lead Asset Against GBS
Comments
$Annexon(ANNX.US$ Did anyone remember to be watching for this? I told Y’all on the 18th to be looking! Hehehe![]()
$Annexon(ANNX.US$ Reuters· 5 mins ago
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting
$Annexon(ANNX.US$
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon announced positive results from its Phase 3 trial of ANX005, an immunotherapy targeting C1q for Guillain-Barré Syndrome (GBS). Presented at the 2024 PNS Annual Meeting, data showed faster and more complete recovery for ANX005-treated patients compared to placebo.
Significant improvements were noted in primary and mult...
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon announced positive results from its Phase 3 trial of ANX005, an immunotherapy targeting C1q for Guillain-Barré Syndrome (GBS). Presented at the 2024 PNS Annual Meeting, data showed faster and more complete recovery for ANX005-treated patients compared to placebo.
Significant improvements were noted in primary and mult...
1
$Annexon(ANNX.US$ Annexon to Present Significant Phase 3 Results of ANX005 in Guillain-Barré Syndrome at PNS Annual Meeting; Potential to Be First Targeted Therapy for GBS! June 22-25, 2024
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg